© BusinessWire
17.12.2025
STAA
LISTED
NASDAQ
Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
News Preview
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to urge its fellow shareholders to vote “AGAINST” the propo...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
ITGR
LISTED
NYSE
Law Offices of Howard G. Smith Encourages Integer Holdings Corporation (ITGR) Shareholders To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) common stock between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”). Integer investors have until February 9, 2026 to file a lead plainti...
Themefolio
Profiler
Peergroup
© Newsfile
17.12.2025
HEAL
LISTED
CSE
Restart Life Announces Food Technology and Research Studies
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an update regarding its previously disclosed intention to fund food-related research initiatives (the "Research Initiatives") in support of its expanding po...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
17.12.2025
VYNE
LISTED
NASDAQ
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. is fair to VYNE shareholders. Upon completion of the proposed transaction, VYNE shareholders are expected to own approximately 3% of the combined company.
Halper Sadeh encourages VYNE shareholders...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
17.12.2025
OSUR
LISTED
NASDAQ
OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates
News Preview
OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
ITGR
LISTED
NYSE
Law Offices of Frank R. Cruz Encourages Integer Holdings Corporation (ITGR) Shareholders To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) common stock between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”). Integer investors have until February 9, 2026 to file a lead pl...
Themefolio
Profiler
Peergroup
© ActuNews
17.12.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – December 17, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on December 16, 2025, from Atlas Special Op...
Themefolio
Profiler
Peergroup
© ActuNews
17.12.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 17 december 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparantiekennisgeving...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
INCY
LISTED
NASDAQ
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
News Preview
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy.
"The EC approval of Minjuvi addresses a critica...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
HUM
LISTED
NYSE
Humana, Nurses on Boards Coalition Announce New Partnership to Mentor Emerging Nurses
News Preview
Humana has announced a new partnership with the national Nurses on Boards Coalition (NOBC) to provide mentors for nursing students.
Humana is providing a gift of $110,000 for first-year funding to support the NOBC’s Mentoring for Success program, which will match 50 nursing students with 50 mentors who work as nurses for Humana.
The mentoring pr...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
STAA
LISTED
NASDAQ
STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
News Preview
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following open letter to STAAR stockholders:
Dear STAAR Surgical Stockholders:
The Special Meeting of Stockholders to vote on the amended agreement with Alcon Inc. (SIX/NYS...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
TNG
LISTED
EURONEXT
Transgene to Participate in Upcoming Investor Meetings
News Preview
Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of:...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
17.12.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
HUM
LISTED
NYSE
Humana Foundation Report Exposes Epidemic of Loneliness Among Underserved Boys
News Preview
The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, today announced the publication of its new report, “Strengthening Belonging for Underserved Boys.” The report explores how loneliness has become a pressing public health issue among boys, particularly those from racially and ethnically diverse backgrounds, rural com...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.12.2025
CRDL
LISTED
TSX
First Berlin Equity Research GmbH: Cardiol Therapeutics Inc | Rating: BUY
News Preview
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.12.2025 / 14:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to co......
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
ACRV
LISTED
NASDAQ
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
News Preview
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpr...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
VTGN
LISTED
NASDAQ
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder d...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
SDGR
LISTED
NASDAQ
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 15, 2025, the company granted restricted stock units (RSUs) with respect to 2,666 shares of the company’s common stock to 6 newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of th...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
News Preview
EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offe...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
TENX
LISTED
NASDAQ
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
News Preview
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
HITC
LISTED
OTC
SafeSpace Global Corporation (OTCID: SSGC) Appoints Harvest Communications as Investor Relations and Corporate Communications Consulting Agency
News Preview
Knoxville, TN, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC), an AI technology company dedicated to protecting lives across education, healthcare, transportation, and correctional environments, today announced the appointment of Harvest Communications as its new investor relations (IR) and corporate communications c...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
KAPA
LISTED
XASE
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
News Preview
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer.
Kairos earned this recognition for its...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
SVRA
LISTED
NASDAQ
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will present and host one on one meetings at the 44th Annual J.P. Morgan Healthcare Conference.
Date/Time of Presentation: Wednesday, January 14, 5:15pm PT/8:15pm ET
Prese...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
CVKD
LISTED
NASDAQ
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
News Preview
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced that members of its management team, including Quang X. Pham, CEO, will hold partnering and investor mee...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
NAYA
LISTED
NASDAQ
INVO Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
News Preview
Signing of definitive purchase agreement represents critical next step in completing previously announced acquisition Signing of definitive purchase agreement represents critical next step in completing previously announced acquisition...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
VASO
LISTED
OTC
Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare
News Preview
Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299...
Themefolio
Profiler
Peergroup
© Newsfile
17.12.2025
BIOV
LISTED
CSE
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delive...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
45870
LISTED
XJPX
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
News Preview
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) announced its second oral peptide therapeutic program entering into its Clinical Development Portfolio – a dual IL-17A and IL-17F macrocyclic peptide inhibitor targeting the major dimeric forms of interleuki...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
NPCE
LISTED
NASDAQ
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
News Preview
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S. Food and Drug Administration (FDA) seeking to expand the labeled indication for its RNS® System to include patients with antisei...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
ATRC
LISTED
NASDAQ
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming J.P. Morgan 44th Annual Healthcare Conference.
AtriCure’s management is scheduled...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
ALNY
LISTED
NASDAQ
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-li...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
OSUR
LISTED
NASDAQ
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
News Preview
Altai Capital Management, L.P. (“Altai”), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter notifying the OraSure Board of Directors (the “Board”) of Altai’s intention t...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
SLP
LISTED
NASDAQ
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026.
Management will host a conference call that...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
